1Chang CC, Chi KH, Kao SJ, et al. Upfront gefitinib/ erlotinib treatmentfollowed by concomitant radiotherapy for advanced lung cancer: Amono-institutional experience [J]. Lung Cancer, 2011, 73 (2): 189-194.
2Wang J, Xia TY, Wang YJ, et al. Prospective study of epidermal growth factor receptor tyrosirte kinase inhihitors concurrent with individualized radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer [J]. Int J Radiat Oncol Biol Phys, 2011, 81 (3) : e59-65.
3Chen G, Feng J, Zhou C, et al. Quality of life (QoL) analyses from OPTIMAL ( CTONG-0802 ), a phase Ill, randomised, open-label study of first-line erIotinib versus chemotherapy in patients with advanced EGFR mutation- positive non-small-cell lung cancer (NSCLC) [J]. Ann Oncol, 2013, 24 (6)z 1615-1622.
4Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma [J]. N EnglJ Med, 2009, 361 (10) 947-957.
5Zhang L, Ma S, Song X, et al. Gefitinib versus placebo as maintenance therapy in patients with locally advanced or metastatic non-small-cell lung cancer ( INFORM: C- TONG0804) : a multicentre, double-blind randomised phase 3 trial [J]. Lancet Oncol, 2012, 13 (5) 466-475.
6Zhou C, Wu YL, Chen G, et al. Erlotinib versus chemotherapy as first-line treatmenl for patients with advanced EGFR mutation-positive non-small-cell lung cancer ( OPTIMAL, CTONG-0802 ) a multicentre, open-label, randomised, phase 3 study [J]. Lancet Oneol, 2011, 12 (8): 735 -742.
7Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial [J]. Lancet Oncol, 2010, 11 (2) 121-128.
8Alexander BM, Othus M, Caglar HB, et al. Tumor volume is a prognostic factor in non-small-cell lung cancer treated with chemoradiotherapy [J]. Int J Radiat Oneol Biol Phys, 2011, 79 (5): 1381-1387.
9Akamatsu H, Inoue A, Mitsudomi T, et a]. Interstitial lung disease associated with gefitinib in Japanese patients with EGFR-mutated non-small-cell lung cancer: combined analysis of two Phase gI trials (NEJ 002 and WJTOG 3405) [J]. Jpn J ClinOncol, 2013, 43 (6): 664-668.
10Eichler AF,Chung E,Kodack DP,et al.The biology of brain metastasestranslation to new therapies [J].Nat Rev Clin Oncol,201 1,8(6):344-56.
